An Official Website of the United States Government
The purpose of this initiative is to improve our ability to detect, prevent, and treat all forms of cardiac arrhythmias. This initiative will encourage small business firms to develop improved diagnostic and therapeutic tools, products, or devices for cardiac arrhythmia monitoring, detection and treatment.
Cardiac arrhythmias represent a major source of public health burden and contribute substantially to morbidity and mortality. For example, atrial fibrillation (AF), the most common sustained cardiac arrhythmia, affects nearly 4% of the US population over 60 years of age and is associated with significantly higher risks of stroke and heart failure. Similarly, ventricular arrhythmias which often result in sudden cardiac arrest and death (SCD) are thought to account for more than 350,000 deaths every year in the US, with an estimated 95% of the victims of out-of-hospital SCD succumbing to death before reaching the hospital.
Although all arrhythmias have in common an abnormal electrical activity in the heart, their causes vary greatly and our understanding of the cellular and molecular signaling pathways and anatomic substrate involved in arrhythmogenesis remains incomplete. There are numerous genetic, environmental, pharmacological, biological, and pathophysiological factors that contribute to arrhythmias. In addition, lethal ventricular arrhythmias may occur without warning or prior indication of heart disease and arrhythmias such as atrial fibrillation may confer risk to patients even when asymptomatic.
NHLBI recently convened two expert panel Working Groups to identify current challenges and future research opportunities in arrhythmia prevention and treatment. Based on the discussions of recent research advances and emerging technologies, the expert panels recommended several broad areas of research and development opportunities for arrhythmia diagnostics and therapeutics. These include: development of better screening assays for disease risk assessment or therapy guidance based on new and emerging discoveries and mechanistic insights (e.g., new gene mutations or polymorphisms, proteomic and/or metabolomic biomarkers, etc.); improvement and optimization of arrhythmia detection algorithms and analyses to improve current device therapies such as pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization devices; development of more effective ablation therapies; and development of noninvasive arrhythmia detection tools such as detection and location of arrhythmia susceptible tissue substrates by anatomical imaging or cardiac tissue conductance mapping approaches. Further information on the Working Group recommendations can be accessed at (http://www.nhlbi.nih.gov/meetings/workshops/modifiers.htm; http://www.nhlbi.nih.gov/meetings/workshops/prevent-af.htm).
This initiative will use the NIH SBIR/STTR research funding mechanism, a two phased research and development (R&D) program aimed at fostering the development of clinically relevant technologies and products such as medical devices and implants, pharmaceuticals, biologics, informatics and biotechnologies. It is designed to encourage interested small business firms to actively seek recent technological or scientific breakthroughs from which to develop new diagnostic and therapeutic tools, devices or products aimed at improved detection, treatment and prevention of all forms of cardiac arrhythmias.
Objectives and scope
The goal of this FOA is to develop innovative methods, tools, technologies and approaches to improve our ability to detect, prevent, and treat arrhythmias.
Examples of research topics might include, but are not limited to the following: